• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝实质组织学对右半肝三叶切除术预后的影响。

Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, Leicester General Hospital, Gwendolen Road, Leicester, UK.

出版信息

J Gastrointest Surg. 2012 Nov;16(11):2064-73. doi: 10.1007/s11605-012-2008-1. Epub 2012 Aug 25.

DOI:10.1007/s11605-012-2008-1
PMID:22923210
Abstract

BACKGROUND

Histological abnormalities in the non-tumour-bearing liver (NTBL) may influence outcome following hepatectomy. Effects will be most pertinent following right trisectionectomy but have yet to be specifically examined in this context. This study aimed to investigate the influence of perioperative factors, including NTBL histology, on outcome following right trisectionectomy.

METHODS

Pathological review of the NTBL of 103 consecutive patients undergoing right trisectionectomy between January 2003 and December 2009 was performed using established criteria for steatosis, non-alcoholic steatohepatitis (NASH), sinusoidal injury (SI), fibrosis and cholestasis. Perioperative and pathological factors were correlated with post-operative outcome (morbidity, major morbidity, hepatic insufficiency and mortality).

RESULTS

Morbidity, hepatic insufficiency and major morbidity occurred in 37.9 %, 14.6 % and 22.3 % of cases, respectively. Ninety-day mortality rate was 5.8 %. NASH (P = 0.007) and perioperative blood transfusion (P = 0.001) were independently associated with hepatic insufficiency following trisectionectomy. NASH (P = 0.028), perioperative transfusion (P = 0.016), diabetes mellitus (P = 0.047) and coronary artery disease (P = 0.036) were independently associated with major morbidity. Steatosis, SI, fibrosis and cholestasis in the NTBL demonstrated no association with any adverse outcome.

CONCLUSION

NASH, but not steatosis or SI, is associated with adverse outcome following right trisectionectomy and caution must be exerted when considering major hepatectomy in patients with NASH.

摘要

背景

非肿瘤肝脏(NTBL)的组织学异常可能会影响肝切除术的结果。这种影响在右三叶切除术最为明显,但尚未在这种情况下专门研究。本研究旨在调查围手术期因素(包括 NTBL 组织学)对右三叶切除术结果的影响。

方法

对 2003 年 1 月至 2009 年 12 月期间连续 103 例接受右三叶切除术的患者的 NTBL 进行了病理复查,使用脂肪变性、非酒精性脂肪性肝炎(NASH)、窦状隙损伤(SI)、纤维化和胆汁淤积的既定标准。将围手术期和病理因素与术后结果(发病率、主要发病率、肝衰竭和死亡率)相关联。

结果

发病率、肝衰竭和主要发病率分别为 37.9%、14.6%和 22.3%。90 天死亡率为 5.8%。NASH(P=0.007)和围手术期输血(P=0.001)与右三叶切除术后肝衰竭独立相关。NASH(P=0.028)、围手术期输血(P=0.016)、糖尿病(P=0.047)和冠状动脉疾病(P=0.036)与主要发病率独立相关。NTBL 的脂肪变性、SI、纤维化和胆汁淤积与任何不良结果均无关。

结论

NASH 但不是脂肪变性或 SI 与右三叶切除术后不良结果相关,在考虑对 NASH 患者进行大肝切除术时应谨慎。

相似文献

1
Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy.肝实质组织学对右半肝三叶切除术预后的影响。
J Gastrointest Surg. 2012 Nov;16(11):2064-73. doi: 10.1007/s11605-012-2008-1. Epub 2012 Aug 25.
2
Role of anatomical right hepatic trisectionectomy for perihilar cholangiocarcinoma.解剖性右三叶切除术在肝门部胆管癌中的作用。
Br J Surg. 2014 Feb;101(3):261-8. doi: 10.1002/bjs.9383. Epub 2014 Jan 8.
3
Left hepatic trisectionectomy for hepatobiliary malignancy: results and an appraisal of its current role.肝左三叶切除术治疗肝胆恶性肿瘤:结果及对其当前作用的评估
Ann Surg. 2005 Aug;242(2):267-75. doi: 10.1097/01.sla.0000171304.70678.11.
4
Clinical significance of left trisectionectomy for perihilar cholangiocarcinoma: an appraisal and comparison with left hepatectomy.左三叶切除术治疗肝门周围胆管癌的临床意义:评价及与左半肝切除术的比较。
Ann Surg. 2012 Apr;255(4):754-62. doi: 10.1097/SLA.0b013e31824a8d82.
5
[Exploration on laparoscopic hepatectomy on central liver tumor: a report of 40 cases].[腹腔镜肝切除术治疗肝中央型肿瘤的探索:附40例报告]
Zhonghua Wai Ke Za Zhi. 2019 Jul 1;57(7):517-522. doi: 10.3760/cma.j.issn.0529-5815.2019.07.008.
6
Clinical outcomes of left hepatic trisectionectomy for hepatobiliary malignancy.左半肝三叶切除术治疗肝胆恶性肿瘤的临床结果。
Br J Surg. 2016 Feb;103(3):249-56. doi: 10.1002/bjs.10059. Epub 2015 Dec 23.
7
Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.新时代肝门部胆管癌的外科治疗: 来自首尔峨山医院的经验。
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):476-89. doi: 10.1007/s00534-009-0204-5. Epub 2009 Oct 23.
8
Right trisectionectomy with principle en bloc portal vein resection for right-sided hilar cholangiocarcinoma: no-touch technique.右三叶切除术联合整块门静脉切除治疗右肝门部胆管癌:无接触技术。
Ann Surg Oncol. 2012 Apr;19(4):1324-5. doi: 10.1245/s10434-011-2072-x. Epub 2011 Oct 15.
9
"Anatomic" right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma.用于肝门部胆管癌的“解剖性”右半肝三叶切除术(扩大右肝切除术)联合尾状叶切除术
Ann Surg. 2006 Jan;243(1):28-32. doi: 10.1097/01.sla.0000193604.72436.63.
10
ALPPS in right trisectionectomy: a safe procedure to avoid postoperative liver failure?右三叶切除术联合联合肝脏离断和门静脉结扎的二步肝切除术:一种避免术后肝衰竭的安全方法?
J Gastrointest Surg. 2013 May;17(5):956-61. doi: 10.1007/s11605-012-2132-y. Epub 2013 Jan 4.

引用本文的文献

1
Current role of trisectionectomy for hepatopancreatobiliary malignancies.肝胰胆恶性肿瘤三分切除术的当前作用
Ann Gastroenterol Surg. 2019 Oct 22;3(6):606-619. doi: 10.1002/ags3.12292. eCollection 2019 Nov.
2
Clinical outcomes of patients with and without diabetes mellitus after hepatectomy: A systematic review and meta-analysis.肝切除术后糖尿病患者与非糖尿病患者的临床结局:一项系统评价和荟萃分析。
PLoS One. 2017 Feb 9;12(2):e0171129. doi: 10.1371/journal.pone.0171129. eCollection 2017.
3
Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes.

本文引用的文献

1
Pathophysiology guided treatment of nonalcoholic steatohepatitis.基于病理生理学的非酒精性脂肪性肝炎治疗策略
J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2(Suppl 2):58-64. doi: 10.1111/j.1440-1746.2011.07018.x.
2
Metabolic syndrome and hepatic resection: improving outcome.代谢综合征与肝切除术:改善预后。
HPB (Oxford). 2011 Dec;13(12):846-59. doi: 10.1111/j.1477-2574.2011.00380.x. Epub 2011 Oct 19.
3
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.荟萃分析:吡格列酮可改善非酒精性脂肪性肝炎患者的肝脏组织学和纤维化。
肝转移瘤:改善个体治疗效果的新概念与生物标志物组合
Clin Exp Metastasis. 2016 Dec;33(8):743-755. doi: 10.1007/s10585-016-9816-8. Epub 2016 Aug 19.
4
A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma.代谢综合征与肝细胞癌关联的临床视角。
J Hepatocell Carcinoma. 2015 Feb 23;2:19-27. doi: 10.2147/JHC.S44521. eCollection 2015.
5
Validation of the peak bilirubin criterion for outcome after partial hepatectomy.部分肝切除术后结局的峰值胆红素标准的验证
HPB (Oxford). 2016 Oct;18(10):806-812. doi: 10.1016/j.hpb.2016.06.003. Epub 2016 Jul 2.
6
Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection.结直肠癌肝转移患者肝切除术前的选择
World J Gastroenterol. 2016 Jan 14;22(2):567-81. doi: 10.3748/wjg.v22.i2.567.
7
Outcomes of simple saline-coupled bipolar electrocautery for hepatic resection.单纯生理盐水耦合双极电凝用于肝切除的疗效
World J Gastroenterol. 2014 Jul 14;20(26):8638-45. doi: 10.3748/wjg.v20.i26.8638.
8
Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?肝脏手术中的代谢综合征与非酒精性脂肪性肝病:新的祸患?
World J Hepatol. 2014 May 27;6(5):306-14. doi: 10.4254/wjh.v6.i5.306.
Aliment Pharmacol Ther. 2012 Jan;35(1):66-75. doi: 10.1111/j.1365-2036.2011.04912.x. Epub 2011 Nov 4.
4
Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease.系统评价非侵入性生物标志物在非酒精性脂肪性肝病评估中的性能。
Liver Int. 2011 Apr;31(4):461-73. doi: 10.1111/j.1478-3231.2011.02451.x. Epub 2011 Feb 1.
5
Chemotherapy-associated liver injury: impact on surgical management of colorectal cancer liver metastases.化疗相关肝损伤:对结直肠癌肝转移手术治疗的影响。
Ann Surg Oncol. 2011 Jan;18(1):181-90. doi: 10.1245/s10434-010-1201-2. Epub 2010 Jul 20.
6
Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection.系统评价和荟萃分析:肝切除术的脂肪变性作为主要危险因素。
Br J Surg. 2010 Sep;97(9):1331-9. doi: 10.1002/bjs.7194.
7
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.对于结直肠癌肝转移患者,术前延长化疗并不能改善病理反应,反而会增加肝切除术后的肝功能不全发生率。
Ann Surg Oncol. 2010 Nov;17(11):2870-6. doi: 10.1245/s10434-010-1166-1. Epub 2010 Jun 22.
8
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.窦状隙阻塞综合征和结节性再生性增生是奥沙利铂相关的常见肝脏病变,贝伐珠单抗可部分预防结直肠肝转移患者的此类肝脏病变。
Histopathology. 2010 Mar;56(4):430-9. doi: 10.1111/j.1365-2559.2010.03511.x.
9
Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.预测结直肠肝转移瘤患者接受奥沙利铂为基础的化疗后发生肝窦阻塞综合征高分级病变:与肝切除术后结局的相关性。
Ann Surg. 2010 Mar;251(3):454-60. doi: 10.1097/SLA.0b013e3181c79403.
10
Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.与奥沙利铂给药相关的门静脉高压:肝窦损伤的临床表现
Clin Colorectal Cancer. 2009 Oct;8(4):225-30. doi: 10.3816/CCC.2009.n.038.